N-carbamylglutamate

Developed for: methylmalonic acidemia · propionic acidemia · carbamoyl phosphate synthetase I deficiency disease · inborn errors of metabolism
Investigated by: Children's Hospital of Philadelphia · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Mendel Tuchman · Boston Children's Hospital · Children's National Research Institute · Lucile Packard Children's Hospital
+3 more
· University Hospitals Cleveland Medical Center · University of California, Los Angeles · University of Colorado, Denver

2009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 22 trials
Phase 2	NCT01597440	Sep 2012 → Feb 2015	methylmalonic acidemia, propionic acidemia	Mendel Tuchman	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01341379	Dec 2010 → Aug 2012	carbamoyl phosphate synthetase I deficiency disease, methylmalonic acidemia, propionic acidemia	Children's Hospital of Philadelphia	Withdrawn	No outcome recorded Stop: Business
Phase 2/31 trial
Phase 2/3	NCT00843921	Aug 2008 → Apr 2018	inborn errors of metabolism	Mendel Tuchman	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	N-carbamylglutamate	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01597440 ↗ 2 NCT00843921 ↗ NCT01341379 ↗
Known as	Carglumic acid	“A drug called N-carbamyl-L-glutamate, Carglumic acid (NCG or Carbaglu)has recently been found to be virtually curative of another urea cycle defect called NAGS deficiency.” NCT01597440 ↗
Known as	N-carbamyl-L-glutamate	“A drug called N-carbamyl-L-glutamate, Carglumic acid (NCG or Carbaglu)has recently been found to be virtually curative of another urea cycle defect called NAGS deficiency.” NCT01597440 ↗
Action	Restore	“can improve or restore ureagenesis capacity” NCT00843921 ↗
Route	Oral	“divided into 4 daily oral doses” NCT01341379 ↗